Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

PubWeight™: 35.34‹?› | Rank: Top 0.01% | All-Time Top 10000

🔗 View Article (PMID 19860577)

Published in Thyroid on November 01, 2009

Authors

American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer1, David S Cooper, Gerard M Doherty, Bryan R Haugen, Bryan R Hauger, Richard T Kloos, Stephanie L Lee, Susan J Mandel, Ernest L Mazzaferri, Bryan McIver, Furio Pacini, Martin Schlumberger, Steven I Sherman, David L Steward, R Michael Tuttle

Author Affiliations

1: The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA. dscooper@jhmi.edu

Associated clinical trials:

Study on HRQOL and Cost-effectiveness Analysis in Management of Patients With <2cm Thyroid Nodules | NCT02398721

Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules | NCT01757834

I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer (CLERAD-PROBE) | NCT01704586

Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules in Type 2 Diabetes (METNODTHYR) | NCT04298684

Articles citing this

(truncated to the top 100)

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid (2016) 12.86

Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid (2011) 8.77

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet (2014) 6.36

Integrated genomic characterization of papillary thyroid carcinoma. Cell (2014) 6.05

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol (2014) 4.75

Risk of thyroid cancer based on thyroid ultrasound imaging characteristics: results of a population-based study. JAMA Intern Med (2013) 3.62

Use of radioactive iodine for thyroid cancer. JAMA (2011) 2.98

The management of thyroid nodules: a retrospective analysis of health insurance data. Dtsch Arztebl Int (2013) 2.97

Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol (2011) 2.96

Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab (2011) 2.93

Preoperative ultrasonography assessment of vocal cord movement during thyroid and parathyroid surgery. World J Surg (2012) 2.89

Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol (2013) 2.80

Euthyroid goiter with and without nodules--diagnosis and treatment. Dtsch Arztebl Int (2012) 2.79

Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid (2014) 2.77

Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid (2010) 2.77

Ultrasonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations. Korean J Radiol (2011) 2.49

Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid (2010) 2.48

Progress in molecular-based management of differentiated thyroid cancer. Lancet (2013) 2.44

Thyroid nodules (≥4 cm): can ultrasound and cytology reliably exclude cancer? World J Surg (2014) 2.40

¹⁸F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study. Eur J Nucl Med Mol Imaging (2014) 2.21

Should small papillary thyroid cancer be observed? A population-based study. Cancer (2014) 2.21

Papillary thyroid microcarcinoma: an over-treated malignancy? World J Surg (2014) 2.15

Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab (2015) 2.14

Fine Needle Aspiration in the Investigation of Thyroid Nodules. Dtsch Arztebl Int (2016) 2.13

Continuous Vagal Nerve Monitoring is Dangerous and Should not Routinely be Done During Thyroid Surgery. World J Surg (2015) 2.10

Risk Factors for Central Compartment Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: A Meta-Analysis. World J Surg (2015) 2.09

The prognostic relevance of psammoma bodies and ultrasonographic intratumoral calcifications in papillary thyroid carcinoma. World J Surg (2013) 2.07

Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid (2014) 2.04

Management of retropharyngeal node metastases from thyroid carcinoma. World J Surg (2015) 1.98

Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer (2011) 1.71

A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid (2010) 1.68

Clinical impact of cervical lymph node involvement and central neck dissection in patients with papillary thyroid carcinoma: a retrospective analysis of 368 cases. Eur Arch Otorhinolaryngol (2011) 1.66

Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer. J Clin Endocrinol Metab (2010) 1.65

In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival. Thyroid (2012) 1.64

Remnant uptake as a postoperative oncologic quality indicator. Thyroid (2013) 1.56

Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations. Korean J Radiol (2012) 1.55

Tumor size measured by preoperative ultrasonography and postoperative pathologic examination in papillary thyroid carcinoma: relative differences according to size, calcification and coexisting thyroiditis. Eur Arch Otorhinolaryngol (2013) 1.52

Completion thyroidectomy: effect of timing on clinical complications and oncologic outcome in patients with differentiated thyroid cancer. World J Surg (2012) 1.50

The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis. J Clin Endocrinol Metab (2013) 1.50

Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg (2011) 1.49

A metabolic phenotype based on mitochondrial ribosomal protein expression as a predictor of lymph node metastasis in papillary thyroid carcinoma. Medicine (Baltimore) (2015) 1.49

Circulating miR-25-3p and miR-451a May Be Potential Biomarkers for the Diagnosis of Papillary Thyroid Carcinoma. PLoS One (2015) 1.47

Differences in postoperative outcomes, function, and cosmesis: open versus robotic thyroidectomy. Surg Endosc (2010) 1.47

Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up. World J Surg (2012) 1.47

[(18)F]FDG PET/CT outperforms [(18)F]FDG PET/MRI in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2015) 1.45

Endocrine Society of India management guidelines for patients with thyroid nodules: A position statement. Indian J Endocrinol Metab (2011) 1.44

Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist (2014) 1.43

Surgeon training and use of radioactive iodine in stage I thyroid cancer patients. Ann Surg Oncol (2012) 1.43

False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer. Am J Nucl Med Mol Imaging (2012) 1.42

The efficacy of lateral neck sentinel lymph node biopsy in papillary thyroid carcinoma. World J Surg (2011) 1.42

Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid (2015) 1.42

Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent. Thyroid (2016) 1.41

All thyroid ultrasound evaluations are not equal: sonographers specialized in thyroid cancer correctly label clinical N0 disease in well differentiated thyroid cancer. Ann Surg Oncol (2014) 1.41

2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J (2013) 1.40

Use of imaging tests after primary treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating death and recurrence. BMJ (2016) 1.39

Engineering Multi-Walled Carbon Nanotube Therapeutic Bionanofluids to Selectively Target Papillary Thyroid Cancer Cells. PLoS One (2016) 1.39

A prospective analysis of thyroidectomy outcomes in a resource-limited setting. World J Surg (2015) 1.38

Use of radioiodine after thyroid lobectomy in patients with differentiated thyroid cancer: does it change outcomes? J Am Coll Surg (2014) 1.38

The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology. Thyroid (2012) 1.34

Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol (2013) 1.31

Image reporting and characterization system for ultrasound features of thyroid nodules: multicentric Korean retrospective study. Korean J Radiol (2012) 1.30

Current status and future perspectives in differentiated thyroid cancer. Endocrinol Metab (Seoul) (2014) 1.29

Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg (2014) 1.26

How I treat late effects in adults after allogeneic stem cell transplantation. Blood (2010) 1.26

Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. Thyroid (2014) 1.25

Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. J Clin Endocrinol Metab (2015) 1.24

Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab (2012) 1.24

Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer (2011) 1.24

German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg (2013) 1.23

RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. J Clin Endocrinol Metab (2013) 1.22

A standardized assessment of thyroid nodules in children confirms higher cancer prevalence than in adults. J Clin Endocrinol Metab (2013) 1.22

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: THE INCREASING INCIDENCE OF THYROID CANCER. Endocr Pract (2015) 1.22

Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. Thyroid (2012) 1.22

The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study. J Clin Endocrinol Metab (2010) 1.22

Follicular adenoma and carcinoma of the thyroid gland. Oncologist (2011) 1.21

Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back. Theranostics (2012) 1.21

A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer (2011) 1.21

The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid (2012) 1.19

Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res (2012) 1.19

Impact of routine unilateral central neck dissection on preablative and postablative stimulated thyroglobulin levels after total thyroidectomy in papillary thyroid carcinoma. Ann Surg Oncol (2011) 1.18

Differentiated thyroid cancer incidentally detected by ¹⁸F-FDG PET/CT: patient's future in a hot-spot? Eur J Nucl Med Mol Imaging (2014) 1.17

New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin (2013) 1.16

Ultrasound elastography for thyroid nodules: recent advances. Ultrasonography (2014) 1.16

Variation in the management of thyroid cancer. J Clin Endocrinol Metab (2013) 1.15

Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications. J Clin Endocrinol Metab (2014) 1.14

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A (2014) 1.14

Robotic thyroidectomy by bilateral axillo-breast approach: review of 1,026 cases and surgical completeness. Surg Endosc (2013) 1.14

Differentiation between benign and malignant solid thyroid nodules using an US classification system. Korean J Radiol (2011) 1.14

Annual financial impact of well-differentiated thyroid cancer care in the United States. Cancer (2014) 1.13

Multifocal papillary thyroid carcinoma--a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg (2013) 1.12

Systematic review of clinical practice guidelines in the diagnosis and management of thyroid nodules and cancer. BMC Med (2013) 1.12

Thyroid ultrasound features and risk of carcinoma: a systematic review and meta-analysis of observational studies. Thyroid (2015) 1.12

Clinical review: Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment. J Clin Endocrinol Metab (2011) 1.11

Ultrasound-Based Risk Stratification for Malignancy in Thyroid Nodules: A Four-Tier Categorization System. Eur Radiol (2015) 1.11

Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review. BMC Surg (2013) 1.10

Minimally invasive video-assisted thyroidectomy: an analysis of results and a revision of indications. Surg Endosc (2011) 1.10

Five-year follow-up of a randomized clinical trial of total thyroidectomy versus Dunhill operation versus bilateral subtotal thyroidectomy for multinodular nontoxic goiter. World J Surg (2010) 1.10

Q-elastography in the presurgical diagnosis of thyroid nodules with indeterminate cytology. PLoS One (2012) 1.10

Perioperative clinical outcomes after robotic thyroidectomy for thyroid carcinoma: a multicenter study. Surg Endosc (2010) 1.09

Articles by these authors

Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2006) 12.23

Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20

The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A (2005) 8.60

Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid (2011) 7.17

Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med (2012) 7.06

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol (2006) 6.57

Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab (2008) 5.94

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71

Cardiac magnetic resonance with edema imaging identifies myocardium at risk and predicts worse outcome in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol (2010) 5.70

Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol (2008) 5.31

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med (2015) 5.07

Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology (2005) 4.96

Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2007) 4.66

Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 4.64

The clinical significance of subclinical thyroid dysfunction. Endocr Rev (2007) 3.80

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol (2010) 3.75

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res (2009) 3.56

Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract (2011) 3.40

Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31

Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab (2009) 3.23

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med (2013) 3.21

Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol (2005) 3.20

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol (2010) 3.11

Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid (2006) 3.03

Upper-airway stimulation for obstructive sleep apnea. N Engl J Med (2014) 2.98

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol (2010) 2.96

The so-called stunning of thyroid tissue. J Nucl Med (2006) 2.86

Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82

Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab (2005) 2.79

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol (2009) 2.77

Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid (2014) 2.77

Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab (2010) 2.74

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab (2007) 2.74

American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid (2012) 2.71

Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg (2002) 2.68

Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. J Nucl Med (2008) 2.47

Progress in molecular-based management of differentiated thyroid cancer. Lancet (2013) 2.44

Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol (2013) 2.43

Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma. Ann Surg (2012) 2.35

Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid (2014) 2.31

Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab (2005) 2.30

Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab (2008) 2.30

Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet (2013) 2.25

Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery (2008) 2.23

Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol (2008) 2.23

Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol (2008) 2.23

Assessment of the cost of fine-needle aspiration cytology as a diagnostic tool in patients with thyroid nodules. Am J Clin Pathol (2008) 2.18

Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol (2006) 2.15

Evidence-based surgical management of substernal goiter. World J Surg (2008) 2.12

The role of radiologic studies in the evaluation and management of primary hyperaldosteronism. Surgery (2008) 2.11

Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ (2007) 2.07

Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab (2007) 2.06

Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. J Nucl Med (2002) 2.05

Thyroid carcinoma. J Natl Compr Canc Netw (2010) 2.02

Micromedullary thyroid cancer: how micro is truly micro? Ann Surg Oncol (2009) 1.99

Management of retropharyngeal node metastases from thyroid carcinoma. World J Surg (2015) 1.98

Neuroendocrine tumors. J Natl Compr Canc Netw (2012) 1.91

Laparoscopic skills are improved with LapMentor training: results of a randomized, double-blinded study. Ann Surg (2006) 1.91

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care (2010) 1.91

Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab (2002) 1.91

Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid (2009) 1.90

RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid (2005) 1.89

Central lymph node dissection in differentiated thyroid cancer. World J Surg (2007) 1.86

Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab (2010) 1.86

Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med (2006) 1.86

The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid (2011) 1.85

Dual oxidase2 is expressed all along the digestive tract. Am J Physiol Gastrointest Liver Physiol (2004) 1.84

The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid (2012) 1.82